More Progress with a Super Targeted Obesity Drug
May 11, 2018 — Two years ago, Rhythm Pharmaceuticals made a big splash with a study showing impressive efficacy for their super targeted obesity drug, setmelanotide. That paper in the New England Journal of Medicine showed setmelanotide could reverse obesity in patients with a rare POMC gene defect. Now, researchers have published new data showing promise in patients with […]